000 | 01890 a2200529 4500 | ||
---|---|---|---|
005 | 20250513091509.0 | ||
264 | 0 | _c19960731 | |
008 | 199607s 0 0 eng d | ||
022 | _a0006-4971 | ||
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aYamauchi, A | |
245 | 0 | 0 |
_aTarget cell-induced apoptosis of interleukin-2-activated human natural killer cells: roles of cell surface molecules and intracellular events. _h[electronic resource] |
260 |
_bBlood _cJun 1996 |
||
300 |
_a5127-35 p. _bdigital |
||
500 | _aPublication Type: Comparative Study; Journal Article | ||
650 | 0 | 4 |
_aAntibodies, Monoclonal _ximmunology |
650 | 0 | 4 |
_aAntigens, CD _ximmunology |
650 | 0 | 4 |
_aApoptosis _xdrug effects |
650 | 0 | 4 | _aBenzoquinones |
650 | 0 | 4 |
_aCD18 Antigens _ximmunology |
650 | 0 | 4 |
_aCell Membrane _xultrastructure |
650 | 0 | 4 |
_aCysteine Endopeptidases _xmetabolism |
650 | 0 | 4 | _aCytotoxicity, Immunologic |
650 | 0 | 4 |
_aDNA _xanalysis |
650 | 0 | 4 | _aFas Ligand Protein |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 |
_aInterleukin-2 _xpharmacology |
650 | 0 | 4 |
_aKiller Cells, Lymphokine-Activated _xcytology |
650 | 0 | 4 |
_aKiller Cells, Natural _xdrug effects |
650 | 0 | 4 | _aLactams, Macrocyclic |
650 | 0 | 4 |
_aLeukemia, Myelogenous, Chronic, BCR-ABL Positive _xpathology |
650 | 0 | 4 |
_aLymphoma, Non-Hodgkin _xpathology |
650 | 0 | 4 |
_aMelanoma _xpathology |
650 | 0 | 4 |
_aMembrane Glycoproteins _xgenetics |
650 | 0 | 4 |
_aProtease Inhibitors _xpharmacology |
650 | 0 | 4 |
_aQuinones _xpharmacology |
650 | 0 | 4 |
_aRecombinant Fusion Proteins _xmetabolism |
650 | 0 | 4 |
_aRifabutin _xanalogs & derivatives |
650 | 0 | 4 |
_aSerine Endopeptidases _xmetabolism |
650 | 0 | 4 | _aTransfection |
650 | 0 | 4 | _aTumor Cells, Cultured |
650 | 0 | 4 |
_afas Receptor _xphysiology |
700 | 1 | _aTaga, K | |
700 | 1 | _aMostowski, H S | |
700 | 1 | _aBloom, E T | |
773 | 0 |
_tBlood _gvol. 87 _gno. 12 _gp. 5127-35 |
|
999 |
_c8651860 _d8651860 |